Anti-Inflammatory Effects of Theophylline and Selective Phosphodiesterase Inhibitors

Allergology International (1996) 45: 125-132 Review Article Anti-inflammatory effects of theophylline and selective phosphodiesterase inhibitors Katharine H Banner and Clive P Page Department of Pharmacology, King's College London, London, UK ABSTRACT of drugs was traditionally thought to be derived from their ability to produce bronchodilatation. However, it is now becoming Theophylline has been used in the treatment of airway dis- increasingly apparent that theophylline, in particular, has both eases, for more than 50 years with benefit thought to be immunomodulatory and anti-inflammatory activity. Although derived from its ability to elicit bronchodilatation. Recent evi- theophylline has been used extensively in the treatment of dence has, however, suggested that theophylline possesses asthma, its molecular mechanism(s) is not clear. Several puta- anti-inflammatory activity. The molecular mechanism of tive mechanisms of action have been suggested to explain the action remains unclear, although inhibition of the phospho- therapeutic effectiveness of theophylline and related xanthines. diesterase (PDE) enzyme, an enzyme which catalyzes the breakdown of cAMP and cGMP, has been proposed. One mechanism that has been proposed is that theophylline, through non-selective phosphodiesterase (PDE) inhibition, Theophylline is a relatively weak inhibitor of PDE although raises intracellular cyclic 3',5'-adenosine monophosphate there is evidence to suggest that PDE activity is elevated in leukocytes from patients with atopic disease. Thus, an altered (cAMP) and cyclic 3',5'-guanosine monophosphate (cGMP) levels resulting in relaxation of airway smooth muscle and inhi- responsiveness to PDE inhibitors may partly explain the bition of inflammatory cell activation. Theophylline is a relatively mechanism of action of theophylline. The PDE enzyme exists weak inhibitor of PDE, although there is evidence to suggest that as the least of seven different isoenzyme forms which can be PDE activity is elevated in leukocytes from patients with atopic characterized on the basis of a number of criteria including disease (atopic dermatitis, asthma, allergic rhinitis),4and thus substrate specificity, sensitivity to selective inhibitors and the an altered responsiveness to PDE inhibitors may partly explain effect of allosteric modulators. The type IV isoenzyme is the the mechanism of action of theophylline. predominant isoenzyme in inflammatory cells although it Seven gene families of the PDE enzyme have so far been exists together with the type III isoenzyme in T-lymphocytes. defined, each of which can be distinguished by a variety of cri- There is considerable evidence from in vitro and in viva stud- teria including their substrate specificity, sensitivity to selective ies suggesting that selective PDE IV inhibitors have anti- inhibitors and the effect of allosteric modulators.5 The type IV inflammatory activity. The following article reviews these isoenzyme appears to be the main isoenzyme of PDE inflamma- studies, together with clinical studies demonstrating that tory cells, although it exists together with the type III isoenzyme in theophylline has anti-inflammatory activity. T cells.6 It is becoming increasingly apparent that theophylline possesses anti-inflammatory and immunomodulatory actions7-9 INTRODUCTION that may well contribute to the clinical efficacy of this drug in the treatment of asthma. Theophylline and related xanthines have been used in the treatment of diseases of the airways for over 50 years and remain widely prescribed drugs world-wide for the treatment of bronchial asthma.1-3 The therapeutic effectiveness of this class EFFECTS OF THEOPHYLLINEAND SELECTIVE PDE ISOENZYME INHIBITORS ON CELLS INVOLVED I N ASTHMA Correspondence: Dr KH Banner, Department of Pharmacology, King's The PDE isoenzymes have now been characterized in many College London, Manresa Road, London SW3 6LX, UK. inflammatory cells and a variety of studies have examined the Received 27 October 1995. Accepted for publication 1 May 1996. potential anti-inflammatory effect of theophylline and selective 126 KH BANNER and CP PAGE PDE isoenzyme inhibitors on these cells. These include mast liferative response.26 The type IV PDE inhibitor, rolipram, was the cells, basophils, lymphocytes, natural killer cells, eosinophils, most effective at inhibiting proliferation whilst the type III and V neutrophils and macrophages. inhibitors only modestly inhibited at high concentrations. In another study, selective inhibitors of the type IV PDE isoenzyme inhibited anti-CD3-stimulated human lymphocyte prolifera- IN VITRO STUDIES tion15 and combined addition of the type III inhibitor, motapi- Effects on mast cells zone, and the type IV inhibitor, rolipram, produced a more Human lung mast cells release a variety of mediators including potent and complete inhibition, an effect which was also seen with the mixed type III-IVinhibitor, zardaverine. Another, very histamine, leukotriene C4 (LTC4)and prostaglandin D2 (PGD2) recent study has found that the proliferation and cytokine secre- which are thought to account for the majority of allergen- tion of T helper (CD4+) and T suppressor (CD8+) cells is inhib- induced bronchoconstriction in allergic asthmatics. Theophyl- ited by type III and IV PDE isoenzyme-selective inhibitors.27 There line has been shown to reduce antigen and anti-IgE receptor is also preliminary evidence to suggest that type IV PDE antibody-stimulated histamine release from rat peritoneal mast inhibitors can inhibit expression of IL-4 and IL-5 genes in The cells10 and reduce histamine release from human basophils.11 cells.28 However, such effects are only seen at concentrations in excess Many studies have examined the effects of selective PDE of those achievable in vivo. Cultured murine mast cells contain inhibitors on mononuclear cell preparations. Type IV PDE a type IV PDE isoenzyme and selective inhibitors of the type IV inhibitors were shown to inhibit N-formyl-met-leu-phe (fMLP)- isoenzyme have also been shown to inhibit histamine release.6 stimulated arachidonic acid29 and tumour necrosis factor-a (TNF-α)30 release from human mononuclearcells. Type IV and Effects on lymphocytes mixed type III-IV PDE inhibitors have also been demonstrated to There is evidence to suggest that activated T cells play a key role inhibit the PHA-stimulated proliferation of human peripheral in the pathogenesis of allergic inflammatory diseases such as blood mononuclear cells (HPBM).24,31In a recent study, the bronchial asthma.12 T cells are likely to play a role in all antigen- atopic PDE IV isoenzyme in mononuclear leukocytes was found driven inflammatory responses since they are the only cell type to be more sensitive to type IV inhibitors than the type IV iso- that directly recognizes and responds to processed antigens. enzyme from normal subjects32 and the type IV inhibitor, RO 20- They are involved in many stages of the allergic response 1724, reduced hyper-IgE synthesis by atopic dermatitis cells in including regulation of IgE production by B cells and recruit- vitro.33 Two studies have also demonstrated that therapeutic lev- ment of other inflammatory cells such as eosinophils. In the mid els of theophylline(10-20μg/mL)can inhibit the tumoricidal 1970s, theophylline was used to produce clones of peripheral activity of natural killer cells.34,35 blood mononuclear cells with possible suppressor cell activity.13 In a more recent study, incubation of peripheral blood lympho- Effects on macrophages cytes with theophylline caused them to suppress autologous cell responses.14 This phenomenon was demonstrated to be due to Airway macrophages arise from circulating monocytes, which a subgroup of T cells which were sensitive to in vitro stimulation mature into macrophages during their residence in the airways. by theophylline.13 Subsequently a number of in vitro investiga- In asthmatic subjects, macrophages release a variety of chemi- tions have suggested that xanthines have the ability to modify cal mediators in response to allergen challenge including lymphocyte behaviour, in particular the ability to inhibit the lym- potent eosinophil chemoattractants like platelet activating fac- phocyte proliferation.15 Two studies reported that theophylline tor (PAF), leukotriene B4 (LTB4)and cytokines. Studies have inhibited T cell proliferation following antigenic16 and mito- demonstrated that after exposure to low therapeutic levels of genic17 stimulation and it has also been shown to diminish E theophylline, peripheral blood mononuclear cells and alveolar rosette formation.18 The synthesis and release of interleukin 2 macrophages obtained from bronchoalveolar lavage fluid (IL-2)is a necessary stimulus for lymphocyte proliferation.19It is (BALF)of normal subjects secrete less superoxide anions in of interest therefore that theophylline has been found to inhibit vitro36 and theophylline has been shown to inhibit opsonized interferon-gamma (IFN-gamma)-induced expression of IL-2 zymosan-stimulated H2O2 generation from human alveolar receptors on a cultured lymphocyte line.20 Theophylline can also macrophages.37 In addition, theophylline and IBMX inhibit the inhibit production16 and release2' of IL-2. generation of the potent eosinophil chemoattractants, PAF, Type III and IV PDE isoenzymes have been characterized in T complement C2 and LTB4 from human monocytes,38,39 and also cells22,23and selective inhibitors of the type III and IV PDE iso- the synthesis and release ofTNFafrom human peripheral blood

Load more